Glenmark Pharmaceuticals Inc, the US-based unit of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), has launched its Acetylcysteine Injection, according to a Monday filing to the Indian stock exchanges.
Glenmark acquired the ANDA (abbreviated new drug application) for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) single-dose vials from Aspen Pharma USA.
The injection is expected to have the same therapeutic effect as Cumberland Pharmaceuticals' listed drug product Acetadote Injection.
As per the IQVIATM sales data, the Acetadote Injection achieved annual sales of around $15.2 million for the 12 months that ended in January.
Shares of the company were up nearly 3% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。